EODData

MEMBERSHIP REGISTER LOG IN

FRA, UNC0: UCB S.A. UNSP.ADR 1/2

07 Nov 2025
LAST:

110.0

CHANGE:
 3.00		OPEN:
110.0		HIGH:
110.0		ASK:
0.0		VOLUME:
0
CHG(%):
2.80		PREV:
107.0		LOW:
110.0		BID:
0.0		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
07 Nov 25110.0110.0110.0110.00
06 Nov 25107.0107.0107.0107.00
05 Nov 25107.0107.0107.0107.00
04 Nov 25108.0108.0108.0108.00
03 Nov 25109.0109.0109.0109.00
31 Oct 25118.0118.0118.0118.050
30 Oct 25117.0117.0117.0117.050
29 Oct 25112.0112.0112.0112.050
28 Oct 25119.0119.0119.0119.050
27 Oct 25116.0116.0116.0116.050

COMPANY PROFILE

Name:UCB S.A. UNSP.ADR 1/2
About:UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet/Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops doxecitine/doxribtimine for TK2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; UCB0222 for the treatment of Parkinson's disease; and UCB9741 and UCB1381 for atopic dermatitis. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Sector:Healthcare
Industry:Biotechnology
Address:Allée de la Recherche, 60, Brussels, Belgium, 1070
Website:https://www.ucb.com
ISIN:US9034801012
LEI:2138008J191VLSGY5A09

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:31.78 
Forward P/E:20.58 
Price to Sales:6.09 
Price to Book:2.14 
Profit Margin:0.19 
Operating Margin:0.20 
Return on Assets:0.05 
Return on Equity:0.14 
DivYield:0.01 
Div/Share:1.39 
Revenue:6.848B 
EBITDA:1.524B 
Shares:379.99M 
Market Cap:41.799B 

TECHNICAL INDICATORS

MA5:108.201.7%
MA10:112.302.1%
MA20:118.758.0%
MA50:111.561.4%
MA100:99.8510.2%
MA200:91.2220.6%
STO9:25.00
STO14:16.67 
RSI14:33.33 
WPR14:-83.33 
MTM14:-15.00
ROC14:-0.12 
ATR:3.00 
Week High:118.007.3%
Week Low:107.002.8%
Month High:129.0017.3%
Month Low:107.0020.6%
Year High:129.0017.3%
Year Low:65.9066.9%

RECENT DIVIDENDS

Date Amount
28 Apr 2025$0.68
26 Apr 2024$0.62
02 May 2023$0.63
28 Apr 2023$0.63
29 Apr 2022$0.59
07 May 2021$0.65